PS 938285

Drug Profile

PS 938285

Alternative Names: PS-938285

Latest Information Update: 11 Jul 2007

Price : $50

At a glance

  • Originator Pharmacopeia Drug Discovery; Schering-Plough
  • Class
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 11 Jul 2007 Discontinued - Phase-I for Respiratory tract disorders in USA (unspecified route)
  • 24 May 2005 This compound is still in active development
  • 12 Jan 2004 Phase-I clinical trials in Respiratory tract disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top